Experimental cancer drug DCC-3084 tested in early trial
NCT ID NCT06287463
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrink. However, the trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DCC-3084 (oral drug)
- What this could lead to
- If successful, this could point toward a new treatment option for certain advanced cancers driven by MAPK pathway mutations.
- What could go wrong
- This is a very early (Phase 1/2) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
SCRI Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
SCRI HealthONE
Denver, Colorado, 80218, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
University of Southern California - Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can your own immune cells beat advanced cancer?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Can new drug cocktails reawaken the immune system against melanoma?
- Blood and gut clues may flag pancreatic cancer risk early